Novo hit by insulin rejection

Shares in Novo Nordisk tanked 13 per cent yesterday after US regulators rejected its new long-acting insulin Tresiba until it conducts extra tests for potential heart risks, dealing a major blow to a key product for the Danish drugmaker. The firm said the Food and Drug Administration’s decision would make it harder to meet long-term financial targets as it cannot provide the data until at least next year.